Also found in: Wikipedia.
ICoSWorkshop on Inference in Computational Semantics
ICOSInducible Co-Stimulator
ICOSInternational Council of Onomastic Sciences
ICOSIrish Co-Operative Organisation Society
ICOSInternational Centre for Olympic Studies (University of Western Ontario; Canada)
ICOSIntegrated Court Operations System (UK)
ICOSGesellschaft für Industrielle Communications-Gesellschaft
References in periodicals archive ?
ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients.
Where To Find Additional Information About The Merger Between ICOS And Lilly
ICOS Corporation (NASDAQ:ICOS) announced today that an agreement has been reached to amend the terms of the merger agreement with Eli Lilly and Company (NYSE:LLY), which was originally signed on October 16, 2006.
Also, an archived replay of the conference webcast will be available on the ICOS website for 90 days.
ICOS Corporation (ICOS) (NASDAQ: ICOS), announced today that it has signed a definitive agreement to be acquired by Eli Lilly and Company (Lilly) (NYSE: LLY).
Noels said, "For about 25 years, ICOS has consistently executed a growth strategy of sustaining market leadership, increasing penetration of established market segments and expanding addressable market.
Research will be performed at the IMEC laboratories and ICOS will provide technology and equipment for inspection and metrology.
Webcast connection through the ICOS Web site at www.
This product, the outcome of a five-year new product program at ICOS and the company's most sizeable investment in new product development ever, illustrates ICOS' abiding commitment to research and development as a means of sustaining its technological leadership.
We are very excited about the prospect of bringing Cialis Once-A-Day to the market in North America and Europe," stated Paul Clark, ICOS Chairman and CEO.
Blair, Chairman and Chief Executive Officer of Dyax commented, "I'm pleased with the industry recognition of the value of our antibody technology and the sustained growth in Dyax's revenue-generating collaborations, as evidenced by this addition of ICOS to our long list of licensees.